bpc-157 fda warning human use not approved advisory committee votes to add popular peptide to drug compounding list bpc 157 human clinical trials

If material is not included in the articles Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder

Etiology Genetics COL5A1 or COL5A2 mutation in 40-50% important in proper assembly of skin matrix collagen fibrils and basement membrane less common mutations identified below Associated conditions Connective tissue disorder characterized by hyperelastic/fragile skin joint hypermobility and dislocation generalized ligamentous laxity poor wound healing early onset arthritis additional features soft tissue and bone fragility soft tissue calcification mitral valve prolapse aortic root dilatation developmental dysplasia of the hip clubfoot pes planus scoliosis high palate gastroparesis Classification Berlin Classification (1988) - revised Types I - XI exist Types II and III - most common and least disabling Villefranche Classification (1998) Presentation Symptoms double-jointedness easily damaged, bruised, & stretchy skin easy scarring & poor wound healing increased joint mobility, joint popping, early arthritis especially shoulders, patellae, ankles chronic musculoskeletal pain (50%) Physical exam a score of 5 or more on 9-point Beighton-Horan scale defines joint hypermobility

Tesamorelin is prepared as an acetate salt

Deutch B, Jorgensen EB, Hansen JC

Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T

A: $400-600 for 20-week protocol using 30mg vials